CSIMarket
 


Corvus Pharmaceuticals Inc   (CRVS)
Other Ticker:  
 

Corvus Pharmaceuticals Inc 's Quick Ratio

CRVS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the forth quarter 2023, Quick Ratio deteriorated to 3.95 below Corvus Pharmaceuticals Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 78 other companies have achieved higher Quick Ratio than Corvus Pharmaceuticals Inc in forth quarter 2023. While Quick Ratio total ranking has improved so far during the IV Quarter 2023 to 362, from total ranking in the third quarter 2023 at 668.

Explain Quick Ratio?
How much Cash & cash equivalents CRVS´s has?
What are CRVS´s Current Liabilities?


CRVS Quick Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Change -36.11 % -47.78 % -22.63 % -10.52 % 10.94 %
Y / Y Cash & cash equivalent Change -35.82 % -35.17 % -34.74 % -45.24 % -39.09 %
Quick Ratio MRQ 3.95 4.41 4.71 4.16 3.93
CRVS's Total Ranking # 362 # 668 # 377 # 634 # 920
Seq. Current Liabilities Change -5.89 % -7.11 % -5.21 % -22.9 % -23.08 %
Seq. Cash & cash equivalent Change -15.6 % -13.1 % 7.4 % -18.52 % -14.74 %



Quick Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 79
Healthcare Sector # 144
Overall Market # 362


Quick Ratio Statistics
High Average Low
65.06 17.23 3.55
(Sep 30 2018)   (Sep 30 2022)




Financial Statements
Corvus Pharmaceuticals Inc 's Current Liabilities $ 7 Millions Visit CRVS's Balance sheet
Corvus Pharmaceuticals Inc 's Cash & cash equivalent $ 27 Millions Visit CRVS's Balance sheet
Source of CRVS's Sales Visit CRVS's Sales by Geography


Cumulative Corvus Pharmaceuticals Inc 's Quick Ratio

CRVS's Quick Ratio for the trailling 12 Months

CRVS Quick Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities TTM Growth -36.11 % -47.78 % -22.63 % -10.52 % 10.94 %
Y / Y Cash & cash equivalent TTM Growth -35.82 % -35.17 % -34.74 % -45.24 % -39.09 %
Quick Ratio TTM 4.31 4.27 4 4.24 4.79
Total Ranking TTM # 269 # 511 # 3517 # 641 # 4029
Seq. Current Liabilities TTM Growth -5.89 % -7.11 % -5.21 % -22.9 % -23.08 %
Seq. Cash & cash equivalent TTM Growth -15.6 % -13.1 % 7.4 % -18.52 % -14.74 %


On the trailing twelve months basis Current Liabilities decreased faster than Corvus Pharmaceuticals Inc 's average Cash & cash equivalent, this led to increase in in Corvus Pharmaceuticals Inc 's Quick Ratio to 4.31, Quick Ratio remained below CRVS average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 78 other companies have achieved higher Quick Ratio than Corvus Pharmaceuticals Inc . While Quick Ratio overall ranking has improved so far to 269, from total ranking during the twelve months ending third quarter 2023 at 511.

Explain Quick Ratio?
How much Cash & cash equivalents CRVS´s has?
What are CRVS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 79
Healthcare Sector # 151
Within the Market # 269


trailing twelve months Quick Ratio Statistics
High Average Low
14.63 8 4
(Dec 31 2018)   (Jun 30 2023)




Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2023 MRQ Cash & cash equivalentDec 31 2023 MRQ Current Liabilities
Cassava Sciences Inc  10.86 $ 121.136  Millions$ 11.158  Millions
Cymabay Therapeutics Inc   10.70 $ 394.255  Millions$ 36.843  Millions
Spyre Therapeutics Inc   10.61 $ 339.277  Millions$ 31.978  Millions
Ovid Therapeutics Inc   10.35 $ 105.833  Millions$ 10.228  Millions
Cryoport inc   10.05 $ 458.435  Millions$ 45.610  Millions
Aprea Therapeutics Inc   9.82 $ 21.607  Millions$ 2.199  Millions
Virios Therapeutics Inc   9.25 $ 3.317  Millions$ 0.359  Millions
Milestone Pharmaceuticals inc   9.13 $ 66.003  Millions$ 7.226  Millions
Summit Therapeutics Inc   9.13 $ 186.242  Millions$ 20.405  Millions
Neurogene Inc   8.58 $ 197.157  Millions$ 22.973  Millions
Lipella Pharmaceuticals Inc   8.55 $ 3.294  Millions$ 0.385  Millions
Lipocine Inc   8.43 $ 22.036  Millions$ 2.614  Millions
Sol gel Technologies Ltd   8.40 $ 37.996  Millions$ 4.522  Millions
Oncolytics Biotech Inc   8.24 $ 26.743  Millions$ 3.246  Millions
Xoma Corporation  7.86 $ 153.290  Millions$ 19.499  Millions
Alpine Immune Sciences Inc   7.80 $ 327.412  Millions$ 41.980  Millions
Abcellera Biologics Inc   7.60 $ 760.585  Millions$ 100.055  Millions
Bicycle Therapeutics Plc  7.57 $ 526.423  Millions$ 69.537  Millions
Inmed Pharmaceuticals Inc   7.28 $ 9.579  Millions$ 1.316  Millions
Ngm Biopharmaceuticals Inc   7.18 $ 144.185  Millions$ 20.081  Millions
Kronos Bio Inc   7.01 $ 172.997  Millions$ 24.695  Millions
Zentalis Pharmaceuticals Inc   6.96 $ 482.919  Millions$ 69.367  Millions
Werewolf Therapeutics Inc   6.93 $ 134.343  Millions$ 19.378  Millions
Zymeworks Inc   6.71 $ 374.327  Millions$ 55.763  Millions
Generation Bio Co   6.62 $ 264.364  Millions$ 39.914  Millions
Salarius Pharmaceuticals inc   6.61 $ 5.900  Millions$ 0.892  Millions
Anebulo Pharmaceuticals Inc   6.56 $ 6.645  Millions$ 1.014  Millions
Royalty Pharma Plc  6.33 $ 495.310  Millions$ 78.222  Millions
Capricor Therapeutics inc   6.32 $ 39.488  Millions$ 6.250  Millions
Glycomimetics Inc   6.11 $ 41.793  Millions$ 6.835  Millions

Date modified: 2024-03-19T22:37:07+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com